SenzaGen AB (STO:SENZA)

Market Cap	173.59M +1.4%
Revenue (ttm)	59.28M +4.0%
Net Income	-10.97M
EPS	-0.36
Shares Out	32.51M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,380
Open	5.44
Previous Close	5.40
Day's Range	5.28 - 5.44
52-Week Range	4.60 - 6.84
Beta	0.54
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About SenzaGen AB

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Employees: 33
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SENZA

Financial Performance

In 2025, SenzaGen AB's revenue was 57.97 million, an increase of 0.48% compared to the previous year's 57.70 million. Losses were -11.59 million, 3.29% more than in 2024.